Actinium Pharmaceuticals, Inc. (ATNM) Investor Relations Documents

Actinium Pharmaceuticals, Inc. (ATNM) investor relations documents from the company's IR site: 11 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site

Published	Type	Document
2026-08-14	Press release	Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American
2026-06-03	Press release	Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportun
2026-06-01	Press release	Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipe
2026-06-01	Press release	Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tum
2026-05-29	Press release	Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs
2026-05-29	Press release	Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE
2026-05-29	Press release	Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE
2026-05-06	Press release	Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across
2026-04-22	Press release	Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Pros
2026-04-06	Press release	Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechan
2026-02-17	Press release	Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting

ATNM overview · ATNM earnings · ATNM financials · ATNM KPIs · ATNM ownership · ATNM peers · ATNM filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.